Making it Simple to
Access Hyaluronic Acid (HA)
There are enough complexities in today’s healthcare system. Access to HA as a treatment of pain in osteoarthritis (OA) of the knee for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics should not be one of them.
OrthogenRx, Inc. is a medical device company focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA). OA is the most common cause of knee pain, causing sufferers significant pain and disability. OrthogenRx’s products GenVisc*850 and TriVisc* are safe, non-surgical alternatives developed to lubricate the joint and relieve mild to moderate knee pain for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. It is our quest of getting patients back to the things that matter.
OrthogenRx was acquired in December 2021 by Avanos Medical, Inc., a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter. Learn more about AVANOS.